How big is the drugs for vulvovaginal candidiasis market?

While Hospital Clinic segment is altered to an CAGR throughout this forecast period.Global Drugs for Vulvovaginal Candidiasis Market Insights and Forecast to 2028.

Who are the key players in the drugs for vulvovaginal candidiasis market?

Some of the key players are FDA, OTC, Others.

Global Drugs for Vulvovaginal Candidiasis Market Insights and Forecast to 2028

Code: QYRE-Auto-36Y9188

Report

January 2022

Pages:114

QYResearch

Description

Table of Content

Tables & Figures

FEATURED COMPANIES

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

Market Analysis and Insights: Global Drugs for Vulvovaginal Candidiasis Market

Due to the COVID-19 pandemic, the global Drugs for Vulvovaginal Candidiasis market size is estimated to be worth US$ 829.9 million in 2022 and is forecast to a readjusted size of US$ 907.4 million by 2028 with a CAGR of 1.5% during the review period.

Fully considering the economic change by this health crisis, Cream accounting for % of the Drugs for Vulvovaginal Candidiasis global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Hospital & Clinic segment is altered to an % CAGR throughout this forecast period.

The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.

The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%

Global Drugs for Vulvovaginal Candidiasis Scope and Segment

Drugs for Vulvovaginal Candidiasis market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Drugs for Vulvovaginal Candidiasis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Cream

Pessary

Other

Segment by Application

Hospital & Clinic

Pharmacy

BY COMPANY

Bayer

Perrigo

J & J

Pfizer

Bristol-Myers Squibb

Effik

Teva

Sanofi

Cisen Pharmaceutical

Kingyork Group

BY REGION

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

FEATURED COMPANIES

1 Study Coverage

1.1 Drugs for Vulvovaginal Candidiasis Product Introduction

1.2 Market by Type

1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Cream

1.2.3 Pessary

1.2.4 Other

1.3 Market by Application

1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Hospital & Clinic

1.3.3 Pharmacy

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Drugs for Vulvovaginal Candidiasis Sales Estimates and Forecasts 2017-2028

2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Estimates and Forecasts 2017-2028

2.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2017 VS 2021 VS 2028

2.4 Global Drugs for Vulvovaginal Candidiasis Sales by Region

2.4.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region (2017-2022)

2.4.2 Global Sales Drugs for Vulvovaginal Candidiasis by Region (2023-2028)

2.5 Global Drugs for Vulvovaginal Candidiasis Revenue by Region

2.5.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2017-2022)

2.5.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2023-2028)

2.6 North America

2.7 Europe

2.8 Asia-Pacific

2.9 Latin America

2.10 Middle East & Africa

3 Competition by Manufacturers

3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers

3.1.1 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Sales (2017-2022)

3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2017-2022)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Drugs for Vulvovaginal Candidiasis in 2021

3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers

3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2017-2022)

3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2017-2022)

3.2.3 Global Top 10 and Top 5 Companies by Drugs for Vulvovaginal Candidiasis Revenue in 2021

3.3 Global Drugs for Vulvovaginal Candidiasis Sales Price by Manufacturers (2017-2022)

3.4 Analysis of Competitive Landscape

3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4.3 Global Drugs for Vulvovaginal Candidiasis Manufacturers Geographical Distribution

3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type

4.1.1 Global Drugs for Vulvovaginal Candidiasis Historical Sales by Type (2017-2022)

4.1.2 Global Drugs for Vulvovaginal Candidiasis Forecasted Sales by Type (2023-2028)

4.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2028)

4.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type

4.2.1 Global Drugs for Vulvovaginal Candidiasis Historical Revenue by Type (2017-2022)

4.2.2 Global Drugs for Vulvovaginal Candidiasis Forecasted Revenue by Type (2023-2028)

4.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2028)

4.3 Global Drugs for Vulvovaginal Candidiasis Price by Type

4.3.1 Global Drugs for Vulvovaginal Candidiasis Price by Type (2017-2022)

4.3.2 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Type (2023-2028)

5 Market Size by Application

5.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application

5.1.1 Global Drugs for Vulvovaginal Candidiasis Historical Sales by Application (2017-2022)

5.1.2 Global Drugs for Vulvovaginal Candidiasis Forecasted Sales by Application (2023-2028)

5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2028)

5.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application

5.2.1 Global Drugs for Vulvovaginal Candidiasis Historical Revenue by Application (2017-2022)

5.2.2 Global Drugs for Vulvovaginal Candidiasis Forecasted Revenue by Application (2023-2028)

5.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2028)

5.3 Global Drugs for Vulvovaginal Candidiasis Price by Application

5.3.1 Global Drugs for Vulvovaginal Candidiasis Price by Application (2017-2022)

5.3.2 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Application (2023-2028)

6 North America

6.1 North America Drugs for Vulvovaginal Candidiasis Market Size by Type

6.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2028)

6.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2028)

6.2 North America Drugs for Vulvovaginal Candidiasis Market Size by Application

6.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2028)

6.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2028)

6.3 North America Drugs for Vulvovaginal Candidiasis Market Size by Country

6.3.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2028)

6.3.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2028)

6.3.3 U.S.

6.3.4 Canada

7 Europe

7.1 Europe Drugs for Vulvovaginal Candidiasis Market Size by Type

7.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2028)

7.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2028)

7.2 Europe Drugs for Vulvovaginal Candidiasis Market Size by Application

7.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2028)

7.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2028)

7.3 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country

7.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2028)

7.3.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2028)

7.3.3 Germany

7.3.4 France

7.3.5 U.K.

7.3.6 Italy

7.3.7 Russia

8 Asia Pacific

8.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Type

8.1.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2028)

8.1.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2028)

8.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Application

8.2.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2028)

8.2.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2028)

8.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Region

8.3.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2017-2028)

8.3.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2017-2028)

8.3.3 China

8.3.4 Japan

8.3.5 South Korea

8.3.6 India

8.3.7 Australia

8.3.8 Taiwan

8.3.9 Indonesia

8.3.10 Thailand

8.3.11 Malaysia

8.3.12 Philippines

9 Latin America

9.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size by Type

9.1.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2028)

9.1.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2028)

9.2 Latin America Drugs for Vulvovaginal Candidiasis Market Size by Application

9.2.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2028)

9.2.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2028)

9.3 Latin America Drugs for Vulvovaginal Candidiasis Market Size by Country

9.3.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2028)

9.3.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2028)

9.3.3 Mexico

9.3.4 Brazil

9.3.5 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Type

10.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2028)

10.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2028)

10.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Application

10.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2028)

10.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2028)

10.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Country

10.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2028)

10.3.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2028)

10.3.3 Turkey

10.3.4 Saudi Arabia

11 Company Profiles

11.1 Bayer

11.1.1 Bayer Corporation Information

11.1.2 Bayer Overview

11.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Bayer Recent Developments

11.2 Perrigo

11.2.1 Perrigo Corporation Information

11.2.2 Perrigo Overview

11.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Perrigo Recent Developments

11.3 J & J

11.3.1 J & J Corporation Information

11.3.2 J & J Overview

11.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 J & J Recent Developments

11.4 Pfizer

11.4.1 Pfizer Corporation Information

11.4.2 Pfizer Overview

11.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 Pfizer Recent Developments

11.5 Bristol-Myers Squibb

11.5.1 Bristol-Myers Squibb Corporation Information

11.5.2 Bristol-Myers Squibb Overview

11.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Bristol-Myers Squibb Recent Developments

11.6 Effik

11.6.1 Effik Corporation Information

11.6.2 Effik Overview

11.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Effik Recent Developments

11.7 Teva

11.7.1 Teva Corporation Information

11.7.2 Teva Overview

11.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Teva Recent Developments

11.8 Sanofi

11.8.1 Sanofi Corporation Information

11.8.2 Sanofi Overview

11.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.8.5 Sanofi Recent Developments

11.9 Cisen Pharmaceutical

11.9.1 Cisen Pharmaceutical Corporation Information

11.9.2 Cisen Pharmaceutical Overview

11.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.9.5 Cisen Pharmaceutical Recent Developments

11.10 Kingyork Group

11.10.1 Kingyork Group Corporation Information

11.10.2 Kingyork Group Overview

11.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2017-2022)

11.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

11.10.5 Kingyork Group Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis

12.2 Drugs for Vulvovaginal Candidiasis Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Drugs for Vulvovaginal Candidiasis Production Mode & Process

12.4 Drugs for Vulvovaginal Candidiasis Sales and Marketing

12.4.1 Drugs for Vulvovaginal Candidiasis Sales Channels

12.4.2 Drugs for Vulvovaginal Candidiasis Distributors

12.5 Drugs for Vulvovaginal Candidiasis Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

13.1 Drugs for Vulvovaginal Candidiasis Industry Trends

13.2 Drugs for Vulvovaginal Candidiasis Market Drivers

13.3 Drugs for Vulvovaginal Candidiasis Market Challenges

13.4 Drugs for Vulvovaginal Candidiasis Market Restraints

14 Key Findings in The Global Drugs for Vulvovaginal Candidiasis Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)

Table 2. Major Manufacturers of Cream

Table 3. Major Manufacturers of Pessary

Table 4. Major Manufacturers of Other

Table 5. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)

Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)

Table 7. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2017-2022) & (K Units)

Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2017-2022)

Table 9. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2023-2028) & (K Units)

Table 10. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2023-2028)

Table 11. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2017-2022) & (US$ Million)

Table 12. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2017-2022)

Table 13. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2023-2028) & (US$ Million)

Table 14. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2023-2028)

Table 15. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2017-2022) & (K Units)

Table 16. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturers (2017-2022)

Table 17. Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2017-2022) & (US$ Million)

Table 18. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2017-2022)

Table 19. Drugs for Vulvovaginal Candidiasis Price by Manufacturers (2017-2022) &(USD/Unit)

Table 20. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 21. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2021)

Table 22. Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Headquarters

Table 23. Manufacturers Drugs for Vulvovaginal Candidiasis Product Offered

Table 24. Date of Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)

Table 27. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2023-2028) & (K Units)

Table 28. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2017-2022)

Table 29. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2023-2028)

Table 30. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2022) & (US$ Million)

Table 31. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2023-2028) & (US$ Million)

Table 32. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2017-2022)

Table 33. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2023-2028)

Table 34. Drugs for Vulvovaginal Candidiasis Price by Type (2017-2022) & (USD/Unit)

Table 35. Global Drugs for Vulvovaginal Candidiasis Price Forecast by Type (2023-2028) & (USD/Unit)

Table 36. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)

Table 37. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2023-2028) & (K Units)

Table 38. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2017-2022)

Table 39. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2023-2028)

Table 40. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2022) & (US$ Million)

Table 41. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2023-2028) & (US$ Million)

Table 42. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2017-2022)

Table 43. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2023-2028)

Table 44. Drugs for Vulvovaginal Candidiasis Price by Application (2017-2022) & (USD/Unit)

Table 45. Global Drugs for Vulvovaginal Candidiasis Price Forecast by Application (2023-2028) & (USD/Unit)

Table 46. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)

Table 47. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2023-2028) & (K Units)

Table 48. North America Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2022) & (US$ Million)

Table 49. North America Drugs for Vulvovaginal Candidiasis Revenue by Type (2023-2028) & (US$ Million)

Table 50. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)

Table 51. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2023-2028) & (K Units)

Table 52. North America Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2022) & (US$ Million)

Table 53. North America Drugs for Vulvovaginal Candidiasis Revenue by Application (2023-2028) & (US$ Million)

Table 54. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022) & (K Units)

Table 55. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2023-2028) & (K Units)

Table 56. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022) & (US$ Million)

Table 57. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2023-2028) & (US$ Million)

Table 58. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)

Table 59. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2023-2028) & (K Units)

Table 60. Europe Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2022) & (US$ Million)

Table 61. Europe Drugs for Vulvovaginal Candidiasis Revenue by Type (2023-2028) & (US$ Million)

Table 62. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)

Table 63. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2023-2028) & (K Units)

Table 64. Europe Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2022) & (US$ Million)

Table 65. Europe Drugs for Vulvovaginal Candidiasis Revenue by Application (2023-2028) & (US$ Million)

Table 66. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022) & (K Units)

Table 67. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2023-2028) & (K Units)

Table 68. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022) & (US$ Million)

Table 69. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2023-2028) & (US$ Million)

Table 70. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)

Table 71. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2023-2028) & (K Units)

Table 72. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2022) & (US$ Million)

Table 73. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Type (2023-2028) & (US$ Million)

Table 74. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)

Table 75. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2023-2028) & (K Units)

Table 76. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2022) & (US$ Million)

Table 77. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Application (2023-2028) & (US$ Million)

Table 78. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2017-2022) & (K Units)

Table 79. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2023-2028) & (K Units)

Table 80. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2017-2022) & (US$ Million)

Table 81. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2023-2028) & (US$ Million)

Table 82. Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)

Table 83. Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2023-2028) & (K Units)

Table 84. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2022) & (US$ Million)

Table 85. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Type (2023-2028) & (US$ Million)

Table 86. Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)

Table 87. Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2023-2028) & (K Units)

Table 88. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2022) & (US$ Million)

Table 89. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Application (2023-2028) & (US$ Million)

Table 90. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022) & (K Units)

Table 91. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2023-2028) & (K Units)

Table 92. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022) & (US$ Million)

Table 93. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2023-2028) & (US$ Million)

Table 94. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)

Table 95. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2023-2028) & (K Units)

Table 96. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2022) & (US$ Million)

Table 97. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Type (2023-2028) & (US$ Million)

Table 98. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)

Table 99. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2023-2028) & (K Units)

Table 100. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2022) & (US$ Million)

Table 101. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Application (2023-2028) & (US$ Million)

Table 102. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022) & (K Units)

Table 103. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2023-2028) & (K Units)

Table 104. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022) & (US$ Million)

Table 105. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2023-2028) & (US$ Million)

Table 106. Bayer Corporation Information

Table 107. Bayer Description and Major Businesses

Table 108. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 109. Bayer Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 110. Bayer Recent Developments

Table 111. Perrigo Corporation Information

Table 112. Perrigo Description and Major Businesses

Table 113. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 114. Perrigo Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 115. Perrigo Recent Developments

Table 116. J & J Corporation Information

Table 117. J & J Description and Major Businesses

Table 118. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 119. J & J Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 120. J & J Recent Developments

Table 121. Pfizer Corporation Information

Table 122. Pfizer Description and Major Businesses

Table 123. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 124. Pfizer Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 125. Pfizer Recent Developments

Table 126. Bristol-Myers Squibb Corporation Information

Table 127. Bristol-Myers Squibb Description and Major Businesses

Table 128. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 129. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 130. Bristol-Myers Squibb Recent Developments

Table 131. Effik Corporation Information

Table 132. Effik Description and Major Businesses

Table 133. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 134. Effik Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 135. Effik Recent Developments

Table 136. Teva Corporation Information

Table 137. Teva Description and Major Businesses

Table 138. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 139. Teva Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 140. Teva Recent Developments

Table 141. Sanofi Corporation Information

Table 142. Sanofi Description and Major Businesses

Table 143. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 144. Sanofi Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 145. Sanofi Recent Developments

Table 146. Cisen Pharmaceutical Corporation Information

Table 147. Cisen Pharmaceutical Description and Major Businesses

Table 148. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 149. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 150. Cisen Pharmaceutical Recent Developments

Table 151. Kingyork Group Corporation Information

Table 152. Kingyork Group Description and Major Businesses

Table 153. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 154. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Model Numbers, Pictures, Descriptions and Specifications

Table 155. Kingyork Group Recent Developments

Table 156. Key Raw Materials Lists

Table 157. Raw Materials Key Suppliers Lists

Table 158. Drugs for Vulvovaginal Candidiasis Distributors List

Table 159. Drugs for Vulvovaginal Candidiasis Customers List

Table 160. Drugs for Vulvovaginal Candidiasis Market Trends

Table 161. Drugs for Vulvovaginal Candidiasis Market Drivers

Table 162. Drugs for Vulvovaginal Candidiasis Market Challenges

Table 163. Drugs for Vulvovaginal Candidiasis Market Restraints

Table 164. Research Programs/Design for This Report

Table 165. Key Data Information from Secondary Sources

Table 166. Key Data Information from Primary Sources

List of Figures

Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture

Figure 3. Global Drugs for Vulvovaginal Candidiasis Market Share by Type in 2021 & 2028

Figure 3. Cream Product Picture

Figure 4. Pessary Product Picture

Figure 5. Other Product Picture

Figure 6. Global Drugs for Vulvovaginal Candidiasis Market Share by Application in 2021 & 2028

Figure 7. Hospital & Clinic

Figure 8. Pharmacy

Figure 9. Drugs for Vulvovaginal Candidiasis Report Years Considered

Figure 10. Global Drugs for Vulvovaginal Candidiasis Sales 2017-2028 (K Units)

Figure 11. Global Drugs for Vulvovaginal Candidiasis Revenue, (US$ Million), 2017 VS 2021 VS 2028

Figure 12. Global Drugs for Vulvovaginal Candidiasis Revenue 2017-2028 (US$ Million)

Figure 13. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region in Percentage: 2021 Versus 2028

Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2017-2022)

Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2023-2028)

Figure 16. North America Drugs for Vulvovaginal Candidiasis Sales YoY (2017-2028) & (K Units)

Figure 17. North America Drugs for Vulvovaginal Candidiasis Revenue YoY (2017-2028) & (US$ Million)

Figure 18. Europe Drugs for Vulvovaginal Candidiasis Sales YoY (2017-2028) & (K Units)

Figure 19. Europe Drugs for Vulvovaginal Candidiasis Revenue YoY (2017-2028) & (US$ Million)

Figure 20. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales YoY (2017-2028) & (K Units)

Figure 21. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue YoY (2017-2028) & (US$ Million)

Figure 22. Latin America Drugs for Vulvovaginal Candidiasis Sales YoY (2017-2028) & (K Units)

Figure 23. Latin America Drugs for Vulvovaginal Candidiasis Revenue YoY (2017-2028) & (US$ Million)

Figure 24. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales YoY (2017-2028) & (K Units)

Figure 25. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue YoY (2017-2028) & (US$ Million)

Figure 26. The Drugs for Vulvovaginal Candidiasis Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021

Figure 27. The Top 5 and 10 Largest Manufacturers of Drugs for Vulvovaginal Candidiasis in the World: Market Share by Drugs for Vulvovaginal Candidiasis Revenue in 2021

Figure 28. Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021

Figure 29. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2028)

Figure 30. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2028)

Figure 31. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2028)

Figure 32. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2028)

Figure 33. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2028)

Figure 34. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2028)

Figure 35. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2028)

Figure 36. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2028)

Figure 37. North America Drugs for Vulvovaginal Candidiasis Sales Share by Country (2017-2028)

Figure 38. North America Drugs for Vulvovaginal Candidiasis Revenue Share by Country (2017-2028)

Figure 39. U.S. Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 40. Canada Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 41. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2028)

Figure 42. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2028)

Figure 43. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2028)

Figure 44. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2028)

Figure 45. Europe Drugs for Vulvovaginal Candidiasis Sales Share by Country (2017-2028)

Figure 46. Europe Drugs for Vulvovaginal Candidiasis Revenue Share by Country (2017-2028)

Figure 47. Germany Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 48. France Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 49. U.K. Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 50. Italy Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 51. Russia Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 52. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2028)

Figure 53. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2028)

Figure 54. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2028)

Figure 55. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2028)

Figure 56. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Share by Region (2017-2028)

Figure 57. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Share by Region (2017-2028)

Figure 58. China Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 59. Japan Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 60. South Korea Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 61. India Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 62. Australia Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 63. Taiwan Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 64. Indonesia Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 65. Thailand Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 66. Malaysia Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 67. Philippines Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 68. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2028)

Figure 69. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2028)

Figure 70. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2028)

Figure 71. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2028)

Figure 72. Latin America Drugs for Vulvovaginal Candidiasis Sales Share by Country (2017-2028)

Figure 73. Latin America Drugs for Vulvovaginal Candidiasis Revenue Share by Country (2017-2028)

Figure 74. Mexico Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 75. Brazil Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 76. Argentina Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 77. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2028)

Figure 78. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2028)

Figure 79. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2028)

Figure 80. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2028)

Figure 81. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Share by Country (2017-2028)

Figure 82. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Share by Country (2017-2028)

Figure 83. Turkey Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 84. Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 85. U.A.E Drugs for Vulvovaginal Candidiasis Revenue (2017-2028) & (US$ Million)

Figure 86. Drugs for Vulvovaginal Candidiasis Value Chain

Figure 87. Drugs for Vulvovaginal Candidiasis Production Process

Figure 88. Channels of Distribution

Figure 89. Distributors Profiles

Figure 90. Bottom-up and Top-down Approaches for This Report

Figure 91. Data Triangulation

Figure 92. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (10% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Drugs for Vulvovaginal Candidiasis Market Insights and Forecast to 2028

Published Date: January 2022

Report Code: QYRE-Auto-36Y9188

Global Drugs for Vulvovaginal Candidiasis Market Insights and Forecast to 2028

FEATURED COMPANIES

Segment by Type

Segment by Application

BY COMPANY

BY REGION

FEATURED COMPANIES

FEATURED COMPANIES

HAVE A QUERY?

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-34R905

Mon Apr 15 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-34L14446

Mon Apr 15 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-16Y2908

Mon Apr 15 00:00:00 UTC 2024

120 Pages

Type: Report

Code: QYRE-Auto-2P6528

Mon Apr 15 00:00:00 UTC 2024

Support Contacts

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

POLICIES

THE COMPANY

CUSTOMER SUPPORT

OUR PRODUCTS

POLICES

Copyright © 2018 Valuates.com. All Rights Reserved.

Sitemap - Privacy Policy - Terms & Conditions